Zobrazeno 1 - 10
of 23
pro vyhledávání: '"Shaheen A. Farhadi"'
Autor:
Brittany D. Partain, Evelyn Bracho-Sanchez, Shaheen A. Farhadi, Elena G. Yarmola, Benjamin G. Keselowsky, Gregory A. Hudalla, Kyle D. Allen
Publikováno v:
Arthritis Research & Therapy, Vol 25, Iss 1, Pp 1-15 (2023)
Abstract Objective Osteoarthritis (OA) is driven by low-grade inflammation, and controlling local inflammation may offer symptomatic relief. Here, we developed an indoleamine 2,3-dioxygenase and galectin-3 fusion protein (IDO-Gal3), where IDO increas
Externí odkaz:
https://doaj.org/article/e4cad2fb4f1445438b5bcb16caeb3f69
Publikováno v:
Frontiers in Chemistry, Vol 7 (2020)
Galectin-1 (G1) and galectin-3 (G3) are carbohydrate-binding proteins that can signal apoptosis in T cells. We recently reported that a synthetic tetramer with two G1 and two G3 domains (“G1/G3 Zipper”) induces Jurkat T cell death more potently t
Externí odkaz:
https://doaj.org/article/887f2e9675a74dd29f88eb4d65be948b
Autor:
Shaheen A. Farhadi, Evelyn Bracho-Sanchez, Margaret M. Fettis, Dillon T. Seroski, Sabrina L. Freeman, Antonietta Restuccia, Benjamin G. Keselowsky, Gregory A. Hudalla
Publikováno v:
Nature Communications, Vol 9, Iss 1, Pp 1-14 (2018)
The use of enzymes as drugs requires that they persist within target tissues over therapeutically relevant time frames. Here the authors use a galectin-3 fusion to anchor enzymes at injection sites for up to 14 days.
Externí odkaz:
https://doaj.org/article/99b77a528cc74b09b0fb7568fbf3a3a5
Autor:
Evelyn Bracho-Sanchez, Fernanda G. Rocha, Sean K. Bedingfield, Brittany D. Partain, Sabrina L. Macias, Maigan A. Brusko, Juan M. Colazo, Margaret M. Fettis, Shaheen A. Farhadi, Eric Y. Helm, Kevin Koenders, Alexander J. Kwiatkowski, Antonietta Restuccia, Bethsymarie Soto Morales, Arun Wanchoo, Dorina Avram, Kyle D. Allen, Craig L. Duvall, Shannon M. Wallet, Gregory A. Hudalla, Benjamin G. Keselowsky
Publikováno v:
Nature Biomedical Engineering.
The treatment of chronic inflammation with systemically administered anti-inflammatory treatments is associated with moderate-to-severe side effects, and the efficacy of locally administered drugs is short-lived. Here we show that inflammation can be
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9391c3c29024e4b7138f0211f503d8f1
https://doi.org/10.1038/s41551-023-01025-1
https://doi.org/10.1038/s41551-023-01025-1
Autor:
Janny Piñeiro-Llanes, Camille D. Rodriguez, Shaheen A. Farhadi, Gregory A. Hudalla, Malisa Sarntinoranont, Chelsey S. Simmons
Publikováno v:
Annals of Biomedical Engineering. 50:703-715
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b4f919de6e7c8556e04324b9e8042014
https://doi.org/10.1007/s10439-022-02949-6
https://doi.org/10.1007/s10439-022-02949-6
Publikováno v:
Cell Mol Bioeng
INTRODUCTION: The promise of the natural immunoregulator, Galectin-1 (Gal1), as an immunomodulatory therapeutic is challenged by its unstable homodimeric conformation. Previously, a Gal1 homodimer stabilized via covalent poly(ethylene glycol) diacryl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::98989df4bf1dc44831ec47c9a5653e74
https://doi.org/10.1007/s12195-021-00681-0
https://doi.org/10.1007/s12195-021-00681-0
Autor:
Anthony D. Sorrentino, Antonietta Restuccia, Gregory A. Hudalla, Shaheen A. Farhadi, Andrés Cruz-Sánchez
Publikováno v:
Mol Syst Des Eng
In nature, the precise heterogeneous co-assembly of different protein domains gives rise to supramolecular machines that perform complex functions through the co-integrated activity of the individual protein subunits. A synthetic approach capable of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5908f2b6380e7f8a97ffdf2f196b440d
https://pubmed.ncbi.nlm.nih.gov/35495737
https://pubmed.ncbi.nlm.nih.gov/35495737
Autor:
Sabrina L. Macias, Benjamin G. Keselowsky, Arun Wanchoo, Christina L. Graves, Ali Altitinchi, Shaheen A. Farhadi, Shannon M. Wallet, Fernanda Regina Godoy Rocha, Gregory A. Hudalla
A major challenge in the treatment of chronic inflammatory diseases including periodontal diseases is the development of therapeutics to safely and specifically direct resolution of inflammation in a localized manner. Here we demonstrate the efficacy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c00f89061adf18c47fc606dd94b70172
https://doi.org/10.1101/2021.07.28.454186
https://doi.org/10.1101/2021.07.28.454186
Autor:
Brittany D. Partain, Evelyn Bracho-Sanchez, Shaheen A. Farhadi, Gregory A. Hudalla, Kyle D. Allen, Benjamin G. Keselowsky, Elena G. Yarmola
ObjectiveControlling joint inflammation can improve osteoarthritis (OA) symptoms; however, current treatments often fail to provide long-term effects. We have developed an indoleamine 2,3-dioxygenase and galectin-3 fusion protein (IDO-Gal3). IDO conv
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cd4be42805f3383752284ef8e08468dc
https://doi.org/10.1101/2021.07.21.453247
https://doi.org/10.1101/2021.07.21.453247
Publikováno v:
Biomaterials Science. 7:1852-1862
Galectins are attractive therapeutic candidates to control aberrant immune system activation because they can alter the phenotype and function of various innate and adaptive immune cells. However, use of exogenous galectin-1 (“G1”) and galectin-3
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b82980294f04ae58b0d727aad77d3def
https://doi.org/10.1039/c8bm01631c
https://doi.org/10.1039/c8bm01631c